(Q36280349)

13 August 2017

Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria (English)

1 reference

13 August 2017

1 reference

Eduardo Gutiérrez

1

1 reference

13 August 2017

Isabel Zamora

2

1 reference

13 August 2017

José Antonio Ballarín

3

1 reference

13 August 2017

Yolanda Arce

4

1 reference

13 August 2017

Sara Jiménez

5

1 reference

13 August 2017

Carlos Quereda

6

1 reference

13 August 2017

Teresa Olea

7

1 reference

13 August 2017

Jorge Martínez-Ara

8

1 reference

13 August 2017

Alfons Segarra

9

1 reference

13 August 2017

Carmen Bernis

10

1 reference

13 August 2017

Asunción García

11

1 reference

13 August 2017

Marian Goicoechea

12

1 reference

13 August 2017

Soledad García de Vinuesa

13

1 reference

13 August 2017

Jorge Rojas-Rivera

14

1 reference

13 August 2017

Manuel Praga

15

1 reference

13 August 2017

Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN)

16

1 reference

13 August 2017

6 September 2012

1 reference

Journal of the American Society of Nephrology

13 August 2017

1 reference

13 August 2017

23

1 reference

13 August 2017

10

1 reference

13 August 2017

1753-1760

1 reference

Current therapy for IgA nephropathy

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Genome-wide association study identifies susceptibility loci for IgA nephropathy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Predicting the risk for dialysis or death in IgA nephropathy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

HLA has strongest association with IgA nephropathy in genome-wide analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

The IgA nephropathy treatment dilemma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Factors predicting progression of IgA nephropathies.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Predicting progression in IgA nephropathy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3458461

Clinical course and prognostic factors of clinical early IgA nephropathy

22 September 2018

1 reference

12 December 2020

The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults

1 reference

12 December 2020

Characterization of early IgA nephropathy

1 reference

12 December 2020

Long-standing spontaneous clinical remission and glomerular improvement in primary IgA nephropathy (Berger's disease)

1 reference

12 December 2020

Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses

1 reference

12 December 2020

Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients With Nephrotic Proteinuria

1 reference

12 December 2020

Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy

1 reference

12 December 2020

Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases

1 reference

12 December 2020

1 reference

12 December 2020

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria

1 reference

12 December 2020

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

12 December 2020

Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2012010063

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22956820

1 reference